Chester County News and Community Website
PLYMOUTH MEETING, PA — Harmony Biosciences Holdings Inc. (Nasdaq: HRMY) will participate in the 2026 Cantor Global Healthcare Conference in New York on Sept. 10, putting the Plymouth Meeting pharmaceutical …
Harmony Biosciences Sets Investor Appearance at Cantor Conference Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings Inc. (Nasdaq: HRMY) will participate in the Piper Sandler Virtual CNS Symposium on Thursday, Aug. 13, giving investors an opportunity to hear from …
Harmony Sets Investor Appearance as CNS Strategy Advances Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) reported a 30% increase in second-quarter WAKIX revenue and nearly doubled net income, while advancing several pipeline programs intended to …
Harmony Profit Jumps as WAKIX Revenue Climbs 30% Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings Inc. (Nasdaq: HRMY) will report second-quarter 2026 financial results on Aug. 4 before U.S. markets open, giving investors an updated view of the …
Harmony Biosciences Sets Aug. 4 Earnings Release, Investor Call Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings Inc. (Nasdaq: HRMY) reported preliminary second-quarter WAKIX net product revenue of approximately $261 million, a record for the company, reaffirming its full-year revenue …
Harmony Biosciences Reaffirms Outlook After Record WAKIX Sales Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings (Nasdaq: HRMY) will present at two healthcare-focused investor conferences next week as the rare-disease drug developer engages with investors amid ongoing efforts to …
Harmony Biosciences Schedules Investor Conference Appearances Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) reported 17% first-quarter revenue growth for its narcolepsy drug WAKIX while advancing patent litigation, new formulations and pipeline programs aimed …
Harmony Revenue Rises as WAKIX Franchise Expands Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) will report first-quarter 2026 financial results on Thursday, May 7, 2026, before the opening of U.S. financial markets.
Harmony Biosciences Schedules First-Quarter Earnings Call for May 7 Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) recently appointed Glenn Reicin as chief financial officer, effective immediately, and reaffirmed its 2026 net product revenue guidance of $1.0 …
Harmony Biosciences Appoints Glenn Reicin as CFO, Reaffirms Outlook Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) appointed Peter Anastasiou as chief operating officer and named Troy Ignelzi to its board of directors, while nominating Geno J. …
Harmony Biosciences Appoints COO, Updates Board Membership Read More